Programmed Cell Death 1 Ligand 2 Protein
"Programmed Cell Death 1 Ligand 2 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A costimulatory B7 antigen that has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 RECEPTOR. It is closely-related to CD274 antigen; however, its expression is restricted to DENDRITIC CELLS and activated MACROPHAGES.
| Descriptor ID |
D061027
|
| MeSH Number(s) |
D12.776.467.150.800 D12.776.543.095.800 D23.050.301.285.800 D23.529.168.800
|
| Concept/Terms |
Programmed Cell Death 1 Ligand 2 Protein- Programmed Cell Death 1 Ligand 2 Protein
- CD273 Antigen
- Antigen, CD273
- PD-L2 Ligand
- Ligand, PD-L2
- PD L2 Ligand
- B7-DC Ligand
- B7 DC Ligand
- Ligand, B7-DC
- Antigens, CD273
- CD273 Antigens
- B7-DC Antigen
- Antigen, B7-DC
- B7 DC Antigen
|
Below are MeSH descriptors whose meaning is more general than "Programmed Cell Death 1 Ligand 2 Protein".
Below are MeSH descriptors whose meaning is more specific than "Programmed Cell Death 1 Ligand 2 Protein".
This graph shows the total number of publications written about "Programmed Cell Death 1 Ligand 2 Protein" by people in this website by year, and whether "Programmed Cell Death 1 Ligand 2 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 1 | 2 |
| 2019 | 4 | 1 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Programmed Cell Death 1 Ligand 2 Protein" by people in Profiles.
-
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. J Immunother Cancer. 2019 10 22; 7(1):272.
-
PD1 pathway in immune-mediated myopathies: Pathogenesis of dysfunctional T cells revisited. Neurol Neuroimmunol Neuroinflamm. 2019 05; 6(3):e558.
-
Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies? Turk J Med Sci. 2019 Feb 11; 49(1):265-271.
-
Increased Neutrophil Surface PD-L1 Expression in Tobacco Smokers: Consequences for Anti-PD-1 Treatment. J Acquir Immune Defic Syndr. 2019 02 01; 80(2):e48-e49.
-
Association of PD-L1, PD-L2, and Immune Response Markers in Matched Renal Clear Cell Carcinoma Primary and Metastatic Tissue Specimens. Am J Clin Pathol. 2019 01 07; 151(2):217-225.
-
PDL2+ CD11b+ dermal dendritic cells capture topical antigen through hair follicles to prime LAP+ Tregs. Nat Commun. 2018 12 07; 9(1):5238.
-
Variation in nuclear size and PD-L2 positivity correlate with aggressive chromophobe renal cell carcinoma. Ann Diagn Pathol. 2018 Jun; 34:31-35.
-
Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages. J Immunol. 2017 08 15; 199(4):1516-1525.